InCephalo AG announces that Lauren E. Abrey, MD will join the company as Chief Medical Officer (CMO). Dr. Abrey will lead the clinical and medical programs of INCEPHALO in support of the company’s lead asset, InC01, a novel IL12 drug. She will help further advance INCEPHALO’s platform, addressing the unmet medical need for novel therapies for brain cancer.
“We are delighted to have Lauren join INCEPHALO’s executive management team in this exciting phase for the company. With her vast experience in the field of brain cancer, either as a physician treating patients, as a Vice-Chair of the Neurology Department at Memorial Sloan Kettering Cancer Center or during her roles at Roche and Novartis, she will add tremendous value to our drug development programs” says Dr Carlo Bertozzi, CEO and cofounder of INCEPHALO.
Read the full press release right here
